Format

Send to

Choose Destination
Clin Infect Dis. 2015 Oct 15;61Suppl 3:S95-101. doi: 10.1093/cid/civ608.

Translating the Tuberculosis Research Agenda: Much Accomplished, but Much More to Be Done.

Author information

1
Critical Path to TB Drug Regimens, Critical Path Institute, Tucson, Arizona.
2
Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden.
3
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
4
Division of Infection and Immunity Center for Clinical Microbiology, University College London Biomedical Research Centre at University College Hospitals NHS Trust, London, United Kingdom.

Abstract

Despite the availability of effective diagnostics and curative treatment regimens for tuberculosis, millions of people die each year of this disease. The steady global increase in the number of tuberculosis cases caused by multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis are of major concern, especially in light of the thin tuberculosis drug pipeline. New tuberculosis drugs are undergoing clinical evaluation, and renewed hope comes from fresh approaches to improve treatment outcomes using a range of adjunct host-directed cellular and repurposed drug therapies. Current efforts in developing second-generation and new rapid point-of-care diagnostic assays take advantage of recent genetic and molecular advances. Slow progress in the development of prophylactic and therapeutic vaccines requires increased funding for basic as well as translational research. Although major challenges remain, these can be overcome by cementing our resolve, raising advocacy, bolstering global funder investments, and leveraging more effective collaborations through equitable public-private partnerships.

KEYWORDS:

drug resistance; new treatment regimens; research; resource-limited settings; tuberculosis

PMID:
26409286
PMCID:
PMC4583569
DOI:
10.1093/cid/civ608
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center